Heparin binds to cells at a site adjacent to ACE2, the portal for SARS-CoV-2 infection, and “potently” blocks the virus, which could open up therapy options. (Cell)
The heightened focus on post-viral effects is what’s really novel about lingering heart damage after COVID-19, a piece in The Atlantic suggests.
Nearly 2% of COVID-19 patients sustain a stroke, with “exceedingly high” 34% in-hospital mortality, a meta-analysis showed. (Neurology)
Opportunistic screening for atrial fibrillation (Afib) in seniors at primary care visits didn’t actually increase the detection rate in a pragmatic randomized trial in the Netherlands. (The BMJ)
Johns Hopkins Hospital turned its interactive gaming room for stroke rehabilitation into a staff decompression space during the COVID-19 lockdown.
Outcomes after MI improved, especially for women, from 2008 to 2017. (Circulation)
Sept. 21 marked the 60th anniversary of the first successful mitral valve prosthesis implant. (